Ventricular Tachycardia in "End Stage" Hypertrophic Cardiomyopathy: A Role of Dronedarone

Authors

Sudip Nanda MD, FACP, Lehigh Valley Health NetworkFollow
Matthew W. Martinez, Lehigh Valley Health NetworkFollow

Publication/Presentation Date

12-1-2012

Abstract

Hypertrophic cardiomyopathy (HCM) occurs in 1 in every 500 individuals. It represents the most common cause of sudden cardiac death in those under the age of twenty-five. 3-5% patients with HCM go on to develop the dilated, hypokinetic end stage (ES) HCM with systolic failure. They have a higher incidence of heart failure, sudden deaths and defibrillator shocks. To the best of our knowledge this is first report of successful use of dronedarone for suppression of VT associated with ES HCM.

Volume

60

Issue

6

First Page

637

Last Page

642

ISSN

0026-4725

Published In/Presented At

Nanda, S., Levin, V., & Martinez, M. W. (2012). Ventricular tachycardia in "end stage" hypertrophic cardiomyopathy: a role of dronedarone. Minerva Cardioangiologica, 60(6), 637-642.

Disciplines

Cardiology | Medical Sciences | Medical Specialties | Medicine and Health Sciences

PubMedID

23147440

LVHN link

http://search.ebscohost.com/login.aspx?direct=true&db=mnh&AN=23147440&site=ehost-live&scope=site

Department(s)

Department of Medicine, Cardiology Division

Document Type

Article